Sanofi-Backed AI Drug Discovery Firm Aqemia Secures €60M Series A to Advance Proprietary Pipeline

Jan 31, 2024 21:48 CST Updated 21:48

Aqemia

Innovative Drug Developer

Wendel Growth

Strategic Investment Institutions

Large Venture

Venture Capital Fund

Eurazeo

Multi-Industry Investors

Elaia

Independent Venture Capital Fund

Recently, Paris – Aqemia continues to grow rapidly in its efforts to discover new drugs, with its generative artificial intelligence driven by deep physics. Following the €30 million raised last year, Aqemia has announced an additional €30 million in funding, bringing its Series A round to €60 million. This investment in Aqemia was led by Wendel Growth, with follow-on commitments from the company's long-term partners Bpifrance Large Venture, Eurazeo, and Elaia.

This new investment follows the recent success of AQEMIA-led drug discovery projects and across the entire drug discovery value chain, with one clearer example being the recent $140 million drug discovery collaboration agreement reached with Sanofi.$140 Million! Sanofi Bets on AI Drug Development Company）

Aqemia will use the new funding to accelerate the growth of its wholly-owned drug discovery programs and assets, and further expand its proprietary GenAI and deep physics drug discovery platform. Aqemia's internal pipeline already includes several projects being tested in animals, primarily in oncology and immuno-oncology, with the next phase of projects covering a full range of therapeutic areas.

As Aqemia progresses in its fundraising efforts, it is poised to strengthen its mission of reshaping the drug discovery landscape. By expanding its team with top-tier talent and pushing the boundaries of technology, Aqemia reaffirms its commitment to leading transformative change in a new era of drug discovery innovation.

Maximilien Levsque, CEO and Co-founder of Aqemia, said:"We are embarking on the next chapter of our history to accelerate our drug discovery programs, building a larger proprietary pipeline beyond the projects already tested in animals, and forming a global organization that leverages generative AI and rigorous physics as key tools to achieve excellence in small molecule drug discovery. Aqemia's journey continues: we are advancing into clinical trials."

Aqemia Began in 2019 as a Deep Tech Spin-off from École Normale Supérieure, Possessing a Unique, Award-winning Physical Theory. In Just Three Years, the Company Has Grown into an Impressive Team of Over 50 People, Established and Expanded Multiple Collaborations with Large Pharmaceutical Companies, and Launched Its Own Drug Discovery Pipeline, Encompassing Various Projects Ranging from Hit Generation to In Vivo Testing. Aqemia’s Goal Is to Accelerate Research Projects on a Large Scale, Allowing It to Expand into Dozens of Fully or Partially Owned Drug Candidates and Spin Them Off into Independent Biotech Companies for Clinical Trials.

Follow the official account below to see the world!